

# ROAD TO REPLENISHMENT

BOARD MEETING


**Marie-Ange Saraka-Yao**

6-7 June 2024, Geneva, Switzerland

# Protecting our future

- Gavi will use its market power to pull innovation from manufacturers whilst **reducing vaccine prices across 50% of its portfolio**
- Operational costs will stay lean: **97 cents of every \$1** will go on buying or delivering vaccines

- The **African Vaccine Market Accelerator** will build resilience and support vaccine sovereignty
- **Global health security** preventing outbreaks and largest investment in stockpiles against killer diseases like Ebola, cholera and yellow fever
- >50% of Gavi's vaccines will help countries adapt to the threats of **climate change and Anti-Microbial Resistance**



- Over the next 5 years countries will fund a record percentage of the costs of their vaccines, contributing **>US\$ 4 billion**
- By 2030, one in three of the 73 lower-income countries originally supported by Gavi will be **fully funding their own vaccine programmes**

- The widest portfolio in Gavi's history with 24 life-saving vaccines for this **generation of children to be the most protected ever**
- >100 million young women and girls protected against **cervical cancer**, saving 1.5 million lives
- >50 million children will receive the new **malaria** vaccine

- Gavi will facilitate **1.4 billion individual contact points between families and health services**
- Gavi will strengthen health systems and reach more **women and zero-dose children**

# Protecting our future

In 2026–2030, Gavi will protect the future by:

Catalysing over [US\$ 4 billion] of financial contributions through domestic co-financing and self-funded vaccine programmes.


>US\$ 4bn 

Reducing prices across at least 50% of Gavi's vaccine portfolio, generating up to US\$ 800 million of efficiency savings.

-50% 

Facilitating over [1.4 billion] individual contacts between families and health services, enabling more integrated primary health care and Universal Health Coverage.

>1.4bn 



Standing ready to respond to [at least 150] outbreaks to boost global health security and protect against the threat of future pandemics.

150+ 

Generating at least [US\$ 100 billion] in economic benefits for Gavi implementing countries.

>US\$ 100bn 


Saving the lives of over [1.5 million] girls through the HPV vaccine.

>1.5m 


Vaccinating over [50 million] children against malaria.

>50m 

# 2026-2030 funding scenarios



# IFFIm is core to Gavi's continued ability to scale up vaccines, shape markets and provide flexible and fit for purpose funding for Gavi 6.0 goals



For 2026-2030, Gavi is seeking approx. **[20% = US\$ 2-2.5 billion]** of Gavi's resources through IFFIm

Across all IFFIm donors, that would represent total new contributions of

**Illustrative**

Over 7 years: ~**US\$ 280 million / year**

Over 15 years: ~**US\$ 170 million / year**

*Note: bars not to scale*

# Thank you


# The IO and AVMA launch is to be seen in the strategic perspective of a year of events



**IO & AVMA  
Launch**  
June 20



**Replenishment  
Conference**  
*date tbd*



**today**

